Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McArthur, J. C.
Right arrow Articles by Peroutka, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McArthur, J. C.
Right arrow Articles by Peroutka, S. J.
NEUROLOGY 1989;39:284
© 1989 American Academy of Neurology

Nifedipine in the prophylaxis of classic migraine

A crossover, double-masked, placebo-controlled study of headache frequency and side effects

J. C. McArthur, MBBS, MPH, K. Marek, MD, A. Pestronk, MD, J. McArthur, RN, BSN and S. J. Peroutka, MD, PhD

Department of Neurology, The Johns Hopkins Hospital, 600 N. Wolfe Street, Baltimore, MD (J.C. McArthur, Drs. Marek, Pestronk, and Peroutka, and J. McArthur)
Departments of Neurology and Pharmacology, Stanford University Medical Center, Stanford, CA (Dr. Peroutka).

Twenty-four patients with classic migraine attacks were treated with either nifedipine or placebo for up to 12 weeks. No significant differences were observed between the nifedipine (2.1 ± 0.2) and placebo (2.3 ± 0.2) treatment groups in the monthly frequency of headaches. However, the incidence of side effects was significantly greater (p < 0.001) in the nifedipine (54% of patients) than in the placebo (8% of patients) treatment groups.

Address correspondence and reprint requests to Dr. Peroutka, Departments of Neurology and Pharmacology, Stanford University Medical Center, Stanford, CA 94305.

Supported in part by Pfizer Laboratories and the National Migraine Foundation (S.J.P.).

Received May 18, 1988. Accepted for publication in final form August 5, 1988.




This article has been cited by other articles:


Home page
 NEJMHome page
K.M.A. Welch
Drug Therapy of Migraine
N. Engl. J. Med., November 11, 1993; 329(20): 1476 - 1483.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1989 by AAN Enterprises, Inc.